Amgen prevails against Sanofi and Regeneron

A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha (evolocumab), rejecting a challenge brought by two competitors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

Americas

Sanofi, Regeneron prevail against Amgen at EPO

30 October 2020 French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.

Big Pharma

A deep dive into Regeneron v Kymab

8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.